Trading Signals: SGEN Stock Price Prediction and Forecast (Fri. May. 30, 2003 - Wed. Dec. 13, 2023)(Seattle Genetics, Inc.)
| SGEN latest price $112.4400 (0.55%) ($111.8700 - $114.4800) on Fri. Jan. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.44% (three month average) | RSI | 41 | Latest Price | $112.4400(0.55%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SGEN declines -1.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support SGEN advance at 0% a week (0% probability) XLC(34%) IYT(25%) VFMO(24%) BOTZ(23%) DIA(23%) | Factors Impacting SGEN price | SGEN will decline at least -1.22% in a week (0% probabilities). VIXM(-12%) VXX(-5%) TLT(-1%) UUP(-0%) UNG(2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.22% (StdDev 2.44%) | Hourly BBV | 0 () | Intraday Trend | 0.4% | | | |
|
1 - 5 Day Possible Target | $109.32(-2.77%) | Resistance Level | $113.34 | 5 Day Moving Average | $111.56(0.79%) | 10 Day Moving Average | $112.42(0.02%) | 20 Day Moving Average | $113.34(-0.79%) | To recent high | -7.5% | To recent low | 37.9% | Market Cap | $19.549b | | | | Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. |